Drug profile · INN
bremelanotide acetate
VYLEESI (AUTOINJECTOR)
bremelanotide acetate (VYLEESI (AUTOINJECTOR)) is a melanocortin receptor 4 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — bremelanotide acetate
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
bremelanotide acetate (VYLEESI (AUTOINJECTOR)) is a melanocortin receptor 4 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Melanocortin receptor 4 agonist
Primary target: Melanocortin receptor 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is bremelanotide acetate?
bremelanotide acetate (VYLEESI (AUTOINJECTOR)) is a melanocortin receptor 4 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for bremelanotide acetate?
VYLEESI (AUTOINJECTOR) is a marketed brand name for bremelanotide acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bremelanotide acetate?
bremelanotide acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.